ICON runs clinical trials for drugmakers.
ICON Public Limited Company (ICLR) is expected to report earnings on Wednesday, October 28, 2026, after the close. Estimated release time after close. Consensus EPS estimate is $2.69.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-29 | FY2026 Q2 | $2.55 | $2.35 | -7.8% | $2.06B |
| 2026-05-27 | FY2025 Q4 | $3.13 | $1.95 | -37.7% | $2.11B |
| 2025-10-22 | FY2025 Q3 | $3.28 | $3.31 | +0.9% | $2.04B |
| 2025-07-24 | FY2025 Q2 | $3.19 | $2.31 | -27.6% | $2.02B |
| 2025-05-02 | FY2025 Q1 | $3.11 | $3.19 | +2.6% | $2.00B |
| 2025-02-21 | FY2024 Q4 | $3.41 | $3.18 | -6.7% | $2.04B |
| 2024-10-23 | FY2024 Q3 | $3.84 | $3.35 | -12.8% | $2.03B |
| 2024-07-24 | FY2024 Q2 | $3.68 | $3.75 | +1.9% | $2.12B |
ICLR has beaten consensus EPS in 3 of its last 8 reported quarters.
ICLR reported Jul 29. The highlights: EPS of $2.35 — a miss vs the $2.55 estimate (-8%); revenue of $2.06B — a beat vs the $2B consensus (+3%). Focus now shifts to biotech bookings and large-pharma spend.
See ICLR on the live calendar →